You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today publishes its Q4 and Year-end report for 2019. CEO Peter Nordkild: “We have been very busy during an intensive last quarter of 2019 progressing Sepranolone in all three of our indications; PMDD, menstrual migraine and Tourette syndrome and raising SEK 48 million in a directed share issue.”
Full PDF(Stockholm, 20 February, 2020) Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 21 January 2020, issue 301,724 new shares to Ergomed plc (“Ergomed”), the CRO carrying out Asarina Pharma’s phase IIb PMDD study.
Full PDFToday, on 21 January 2020, Asarina Pharma AB (publ) held an extraordinary general meeting (“EGM”) in Stockholm, Sweden. The EGM elected the chairman of the board of directors Paul de Potocki as chairman of the meeting and advokat Nina Johnsson with Fredersen Advokatbyrå to take minutes at the meeting. The EGM resolved upon, inter alia,…
Full PDFThe shareholders of Asarina Pharma AB (publ) are hereby summoned to attend the Extraordinary General Meeting (“EGM”) on 21 January 2020, at 10.00 at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CET and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice, which…
Full PDFAsarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.
Full PDF